BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zanghì A, D'Amico E, Lo Fermo S, Patti F. Exploring polypharmacy phenomenon in newly diagnosed relapsing-remitting multiple sclerosis: a cohort ambispective single-centre study. Ther Adv Chronic Dis 2021;12:2040622320983121. [PMID: 33717425 DOI: 10.1177/2040622320983121] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Chertcoff A, Ng HS, Zhu F, Zhao Y, Tremlett H. Polypharmacy and multiple sclerosis: A population-based study. Mult Scler 2023;29:107-18. [PMID: 36301629 DOI: 10.1177/13524585221122207] [Reference Citation Analysis]
2 Michelis D, Brunetti N, Solaro C, Mancardi GL, Uccelli A, Inglese M, Laroni A. Ageing with multiple sclerosis: clinical characterization of an elderly population, a cross-sectional study. Multiple Sclerosis and Related Disorders 2022. [DOI: 10.1016/j.msard.2022.104464] [Reference Citation Analysis]
3 Hecker M, Frahm N, Bachmann P, Debus JL, Haker MC, Mashhadiakbar P, Langhorst SE, Baldt J, Streckenbach B, Heidler F, Zettl UK. Screening for severe drug-drug interactions in patients with multiple sclerosis: A comparison of three drug interaction databases. Front Pharmacol 2022;13:946351. [PMID: 36034780 DOI: 10.3389/fphar.2022.946351] [Reference Citation Analysis]
4 Zanghì A, Avolio C, Hartung H, D'amico E. Editorial: Immunosenescence and multiple sclerosis: Prognostic and therapeutic implications. Front Neurol 2022;13:996342. [DOI: 10.3389/fneur.2022.996342] [Reference Citation Analysis]
5 Rezaee M, Morowvat MH, Poursadeghfard M, Radgoudarzi A, Keshavarz K. Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis. BMC Health Serv Res 2022;22. [DOI: 10.1186/s12913-022-07495-4] [Reference Citation Analysis]
6 Zhao Z, Lv Y, Gu ZC, Ma CL, Zhong MK. Risk for Cardiovascular Adverse Events Associated With Sphingosine-1-Phosphate Receptor Modulators in Patients With Multiple Sclerosis: Insights From a Pooled Analysis of 15 Randomised Controlled Trials. Front Immunol 2021;12:795574. [PMID: 34950154 DOI: 10.3389/fimmu.2021.795574] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
7 Concerto C, Rodolico A, Ciancio A, Messina C, Natale A, Mineo L, Battaglia F, Aguglia E. Vitamin D and Depressive Symptoms in Adults with Multiple Sclerosis: A Scoping Review. IJERPH 2021;19:199. [DOI: 10.3390/ijerph19010199] [Reference Citation Analysis]
8 Rajendran R, Böttiger G, Stadelmann C, Karnati S, Berghoff M. FGF/FGFR Pathways in Multiple Sclerosis and in Its Disease Models. Cells 2021;10:884. [PMID: 33924474 DOI: 10.3390/cells10040884] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]